BACKGROUND: Coronavirus disease 2019 (COVID-19) is a new acute espiratory infectious disease that has been in a public health emergency of international concern . In China, the combination of Xuanfei Baidu Formula (XBF) and conventional drug is used in the clinical treatment of patients with new coronary pneumonia, However, there is no comprehensive and systematic evidence on the effectiveness and safety of XBF . MATERIALS AND
METHODS: We search for research in PubMed, China National Knowledge Infrastructure, Wan-fang Database, China Biomedical Database, and Chinese Science Citation Database . For``Xuanfei Baidu Formula"and``COVID-19 ,"we screened suitable articles without language restrictions on keywords, Review Manager 5.3 and STATA 14.2 software was used for the data analysis .
RESULTS: The systematic review and meta-analysis will evaluate the efficacy and safety of XBF combined with conventional drug in the treatment of COVID-19 .
CONCLUSION: We will provide evidence of XBF for the treatment on COVID-19 patients. INPLASY REGISTRATION NUMBER: INPLASY2020120011.